Safety and Tolerability of Everolimus as second-line Treatment on poorly differentiated neuroendocrine carcinoma/ neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine Tumor G3 - an investigator initiated Phase II study
Everolimus (Afinitor®) should be administered orally once daily at the same time every day, consistently either with or without food.
